Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2024 | $30.00 → $8.00 | Buy → Sell | Truist |
| 8/12/2024 | $42.00 → $11.00 | Overweight → Neutral | Piper Sandler |
| 8/12/2024 | $45.00 → $10.00 | Overweight → Underweight | JP Morgan |
| 8/12/2024 | Outperform → Mkt Perform | Raymond James | |
| 8/12/2024 | $37.00 → $14.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 7/3/2024 | $38.00 → $25.00 | Overweight → Equal Weight | Barclays |
| 3/7/2024 | $80.00 → $45.00 | Overweight | JP Morgan |
| 12/20/2023 | $42.00 | Outperform | Raymond James |
PARSIPPANY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced new data demonstrating its gene therapy for osteoarthritis candidate, PCRX-201 (enekinragene inzadenovec), provided sustained improvements in knee pain, stiffness, and function to 104 weeks following local administration, with a well-tolerated safety profile. The data, which indicate a potential for sustained clinical efficacy in patients with moderate to severe osteoarthritis of the knee (OAK), will be presented during a poster session at the American College of Rheumatol
PARSIPPANY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences: Jefferies London Healthcare Conference on Tuesday, November 19th at 3:00PM GMT (10:00AM ET).36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 1:00PM ET. Live audio of the events can be accessed by visiting the "Events" page of the company's website at investor.pacira.com. A replay of the webcasts will also be available for two weeks following the events. About PaciraPacira BioSciences delivers innovative, non-opioid pain therapies to transform
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
10-Q - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
8-K - Pacira BioSciences, Inc. (0001396814) (Filer)
Truist downgraded Pacira BioSciences from Buy to Sell and set a new price target of $8.00 from $30.00 previously
Piper Sandler downgraded Pacira BioSciences from Overweight to Neutral and set a new price target of $11.00 from $42.00 previously
JP Morgan downgraded Pacira BioSciences from Overweight to Underweight and set a new price target of $10.00 from $45.00 previously
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
3 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
4 - Pacira BioSciences, Inc. (0001396814) (Issuer)
Pacira BioSciences (NASDAQ:PCRX) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 2 1 1 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $41.88, with a high estimate of $57.00 and a low estimate of $25.00. Highlighting a 8.72% decrea
Truist Securities analyst Les Sulewski maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to $30.
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
SC 13G/A - Pacira BioSciences, Inc. (0001396814) (Subject)
-- Conference call today at 4:30 p.m. ET -- PARSIPPANY, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today reported financial results for the third quarter of 2024. Third Quarter 2024 Financial Highlights Total revenues of $168.6 millionNet product sales of $132.0 million for EXPAREL, $28.4 million for ZILRETTA, and $5.7 million for iovera°Net loss of $143.5 million, or $3.11 per share (basic and diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $54.7 million See "Non-GAAP Financial Information" below. "2024 continues to be highligh
PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing them to access the live call. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the "Events" page on the Paci
-- Conference call today at 4:30 p.m. ET -- TAMPA, Fla., July 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2024. Second Quarter 2024 Financial Highlights Total revenues of $178.0 millionNet product sales of $136.9 million for EXPAREL, $30.7 million for ZILRETTA, and $5.7 million for iovera°Net income of $18.9 million, or $0.41 per share (basic) and $0.39 per share (diluted)Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $62.1 million See "Non-GAAP Financial Informatio
enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company's 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a three-year term expiring at the 2027 annual meeting of shareholders. enGene's Board is now comprised of seven members including Richard Glickman (Chairman), Gerald Brunk, Jasper Bos, and Jason Hanson. "We are pleased to welcome Paul and Wouter to our Board of
-- Transformational Leader Brings Three Decades of Global Experience in Pharmaceutical and Biotechnology Product Development and Commercialization -- -- Paul J. Hastings Named Chair of the Board -- -- Dave Stack to Remain in Advisory Role through August 2025 -- TAMPA, Fla., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that its Board of Directors (the "Board") has appointed Frank D. Lee as Chief Executive Officer and a member of the Board, effective January 2, 2024. As previously announced in September 2023, David Stack will retire from his r
-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately. "We are pleased to welcome these four highly seasoned executives to our Board of Directors, whose experience will enhance our board as we advance on our strategic objectives across multiple key areas," said Dave Stack, chairman and chief executive